Sponsor

Medivation, Inc.

Clinical research sponsor

Published trials47
Recruiting shown0
Roles2
SourceClinicalTrials.gov

Clinical trials

47 shown
An Extension of the CONCERT Protocol (DIM18)NCT01152216 · lead sponsor · 2010-04-01
TERMINATED
A Safety and Efficacy Study Evaluating Dimebon (Latrepirdine) in Patients With Moderate to Severe Alzheimer's DiseaseNCT00954590 · lead sponsor · 2009-10-01
TERMINATED
Safety and Efficacy Study Evaluating Dimebon in Patients With Mild to Moderate Alzheimer's Disease on DonepezilNCT00829374 · lead sponsor · 2009-03-01
COMPLETED
Safety and Tolerability of Dimebon in Patients on Memantine, and Memantine Plus DonepezilNCT00829816 · lead sponsor · 2008-12-01
COMPLETED
A Safety and Efficacy Study of Oral Dimebon in Patients With Mild-To-Moderate Alzheimer's DiseaseNCT00675623 · lead sponsor · 2008-05-01
COMPLETED
Study of Combination Therapy With Dimebon and Donepezil (Aricept) in Patients With Alzheimer's DiseaseNCT00704782 · lead sponsor · 2008-04-01
TERMINATED
Double-blind, Placebo-controlled Study of Oral Dimebon in Subjects With Mild to Moderate Alzheimer's DiseaseNCT00377715 · lead sponsor · 2005-09-01
COMPLETED
A Trial of Androgen Deprivation, Docetaxel, and Enzalutamide for Metastatic Prostate CancerNCT03246347 · collaborator · 2017-08-23
ACTIVE_NOT_RECRUITING
A Study of Talazoparib in Men With DNA Repair Defects and Metastatic Castration-Resistant Prostate CancerNCT03148795 · collaborator · 2017-07-04
COMPLETED
Efficacy and Safety Study of Enzalutamide in Combination With Paclitaxel Chemotherapy or as Monotherapy Versus Placebo With Paclitaxel in Patients With Advanced, Diagnostic-Positive, Triple-Negative Breast CancerNCT02929576 · collaborator · 2016-09-01
WITHDRAWN
Enzalutamide and Metformin Hydrochloride in Treating Patients With Hormone-Resistant Prostate CancerNCT02339168 · collaborator · 2016-06-22
COMPLETED
Feasibility Study of Adjuvant Enzalutamide for the Treatment of Early Stage AR (+) Triple Negative Breast CancerNCT02750358 · collaborator · 2016-05-19
ACTIVE_NOT_RECRUITING
A Study of Enzalutamide Re-treatment in Metastatic Castration-resistant Prostate Cancer After Docetaxel and/or Cabazitaxel TreatmentNCT02441517 · collaborator · 2015-10-28
TERMINATED
European Observational Study of Enzalutamide in Metastatic Castration Resistant Prostate Cancer (mCRPC)NCT02495974 · collaborator · 2015-09-08
COMPLETED
Randomized Salvage Radiation Therapy Plus Enzalutamide Post ProstatectomyNCT02203695 · collaborator · 2015-03-28
COMPLETED
Enzalutamide/Leuprolide +/- Abiraterone/Pred in ProstateNCT02268175 · collaborator · 2014-10-01
COMPLETED
Neoadjuvant Phase 2 Study Comparing the Effects of AR Inhibition With/Without SRC or MEK Inhibition in Prostate CancerNCT01990196 · collaborator · 2014-09-23
ACTIVE_NOT_RECRUITING
Enzalutamide, Radiation Therapy and Hormone Therapy in Treating Patients With Intermediate or High-Risk Prostate CancerNCT02023463 · collaborator · 2014-04-02
ACTIVE_NOT_RECRUITING
Salvage Therapeutic Radiation With Enzalutamide and ADT in Men With Recurrent Prostate Cancer (STREAM)NCT02057939 · collaborator · 2014-04-01
COMPLETED
Enzalutamide + External Beam Rt For ProstateNCT02028988 · collaborator · 2014-02-01
COMPLETED
Enzalutamide With or Without Abiraterone and Prednisone in Treating Patients With Castration-Resistant Metastatic Prostate CancerNCT01949337 · collaborator · 2014-01-22
UNKNOWN
Efficacy and Safety Study of Enzalutamide in Combination With Exemestane in Patients With Advanced Breast CancerNCT02007512 · collaborator · 2013-12-16
COMPLETED
A Phase 2, 2-Stage, 2-Cohort Study of Talazoparib (BMN 673), in Locally Advanced and/or Metastatic Breast Cancer Patients With BRCA Mutation (ABRAZO Study)NCT02034916 · collaborator · 2013-12-13
TERMINATED
Abiraterone Acetate Plus LHRH Agonist and Abiraterone Acetate Plus LHRH Agonist and EnzalutamideNCT01946165 · collaborator · 2013-10-31
COMPLETED
A Study Evaluating Talazoparib (BMN 673), a PARP Inhibitor, in Advanced and/or Metastatic Breast Cancer Patients With BRCA Mutation (EMBRACA Study)NCT01945775 · collaborator · 2013-10-14
COMPLETED
A Study to Evaluate How Daily Dosing With Enzalutamide Affects the Metabolism of Caffeine and Dextromethorphan in Men With Prostate CancerNCT02225093 · collaborator · 2013-10-02
COMPLETED
Study of Enzalutamide in Patients With Castration-resistant Prostate CancerNCT01942837 · collaborator · 2013-09-13
COMPLETED
A Study to Compare Capsule and Tablet Forms of MDV3100 (Enzalutamide) After Administration of a Single Set Dose Under Fasted Conditions in Healthy Male SubjectsNCT01911741 · collaborator · 2012-11-01
COMPLETED
Relative Bioavailability Study of Enzalutamide in Prostate Cancer PatientsNCT01902251 · collaborator · 2012-11-01
COMPLETED
A Study to Evaluate the Safety and Efficacy of Enzalutamide in Chemotherapy-Naïve, Symptomatic Patients With Metastatic Castration-Resistant Prostate CancerNCT01663415 · collaborator · 2012-08-01
WITHDRAWN
Drug-drug Interaction Study With MDV3100 and a Cocktail of SubstratesNCT01911728 · collaborator · 2011-07-25
COMPLETED
A Study to Test if Enzalutamide is Effective and Safe in Prostate Cancer Patients Who Have Never Had Hormone TherapyNCT01302041 · collaborator · 2011-05-06
COMPLETED
Study of Talazoparib, a PARP Inhibitor, in Patients With Advanced or Recurrent Solid TumorsNCT01286987 · collaborator · 2011-01-03
COMPLETED
An Extension To The B1451006 Protocol To Evaluate The Safety and Efficacy of Dimebon In Subjects With Moderate-to-Severe Alzheimer's DiseaseNCT01066546 · collaborator · 2010-04-01
TERMINATED
A Study To Evaluate The Abuse Potential Of Single Oral Doses Of Dimebon (Latrepirdine) In Healthy Recreational Polydrug UsersNCT00975481 · collaborator · 2009-10-01
COMPLETED
A Study In Healthy Volunteers To Estimate The Pharmacokinetics Of Four Modified-Release Formulations Of Dimebon (Latrepirdine)NCT00988624 · collaborator · 2009-10-01
COMPLETED
A Study Evaluating The Absorption Of Dimebon Into The Body From A Dimebon Solution Applied To The SkinNCT00990613 · collaborator · 2009-10-01
COMPLETED
An Extension To The B1451027 Protocol To Evaluate The Long Term Safety And Tolerability Of Dimebon In Patients With Alzheimer's DiseaseNCT00939783 · collaborator · 2009-09-01
TERMINATED
A Phase 3 Efficacy Study Of Dimebon In Patients With Moderate To Severe Alzheimer's DiseaseNCT00912288 · collaborator · 2009-09-01
TERMINATED
A Phase I Study To Estimate The Effect Of Ketoconazole And Omeprazole On The Pharmacokinetics Of Dimebon In Healthy Subjects Who Are Normal Or Poor CYP2D6 MetabolizersNCT00931073 · collaborator · 2009-07-01
COMPLETED
Dimebon (PF-01913539)-Digoxin Drug-Drug Interaction Study In Healthy SubjectsNCT00831506 · collaborator · 2009-02-01
COMPLETED
A Phase 1, Non-Randomized, Open-Label, Single-Dose Study To Evaluate The Pharmacokinetics, Safety, And Tolerability Of Dimebon [PF 01913539] In Subjects With Severely-Impaired And Normal Renal FunctionNCT00824590 · collaborator · 2009-02-01
COMPLETED
A Phase 1 Study To Evaluate The Pharmacokinetics, Safety, And Tolerability Of Dimebon [PF-01913539] In Japanese And Western Healthy SubjectsNCT00825084 · collaborator · 2009-02-01
COMPLETED
A Phase 1, Randomized, Open-Label, Two-Way Crossover Study To Evaluate The Steady-State Effect Of Dimebon (PF 01913539) On The Single-Dose Pharmacokinetics And Pharmacodynamics Of Warfarin In Healthy SubjectsNCT00827034 · collaborator · 2009-02-01
COMPLETED
A Phase 3 Study To Evaluate The Safety And Tolerability Of Dimebon Patients With Mild To Moderate Alzheimer's DiseaseNCT00838110 · collaborator · 2009-02-01
COMPLETED
A Phase 1 Study To Evaluate The Effect Of Dimebon On The Pharmacokinetics Of DextromethorphanNCT00788047 · collaborator · 2008-11-01
COMPLETED
Provide Expanded Access to MDV3100 and Monitor Its Safety in Patients With Progressive Castration-Resistant Prostate Cancer Previously Treated With Docetaxel-Based ChemotherapyNCT01606982 · collaborator
APPROVED_FOR_MARKETING

Sponsor roles

collaborator40
lead sponsor7

How to interpret this record

CureCurrent links normalized diseases, medicines, registry study labels, sponsors and research sites. A link is not the same as a finding of clinical effectiveness. Our research guides explain how to compare studies, decode RxNorm identities, and avoid over-interpreting site and trial counts. See the published database coverage for mapping completeness.

Registry-derived research relationships: ClinicalTrials.gov. Raw condition and intervention labels remain distinct from canonical MONDO/RxNorm entities unless separately normalized.